Physician profile
Narinder S Arora
NPI 1477576924
$13,160.21
in general payments reported to CMS, 2019-2025
48 companies · $1,671 in 2025
The $1,671 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,877 · 2020: $1,694 · 2021: $2,527 · 2022: $1,768 · 2023: $1,790 · 2024: $1,834 · 2025: $1,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,294.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,516.77 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Lilly USA, LLC | $1,152.14 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $951.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $819.80 | 2019-2025 | Jardiance |
| Mylan Specialty L.P. | $799.91 | 2019-2024 | Yupelri |
| Abbvie INC. | $788.81 | 2021-2025 | Ubrelvy, Viberzi, Linzess |
| Novo Nordisk INC | $700.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $594.07 | 2019-2023 | Austedo Xr, Ajovy |
| Amgen INC. | $486.50 | 2020-2025 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $441.52 | 2019-2025 | |
| Pfizer INC. | $352.78 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $316.50 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $292.64 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $248.51 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $237.45 | 2019-2023 | Eliquis |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $231.60 | 2019-2022 | |
| Daiichi Sankyo INC. | $221.38 | 2021-2023 | Injectafer |
| Paratek Pharmaceuticals, INC. | $193.14 | 2023-2025 | Nuzyra, Xhance |
| Grifols USA, LLC | $186.94 | 2019-2021 | |
| Viatris Specialty LLC | $180.13 | 2025 | Yupelri |
| Philips North America LLC | $161.78 | 2022-2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $122.00 | 2019-2021 | |
| Uswm, LLC | $113.78 | 2022-2023 | Lucemyra, Zimhi |
| Axsome Therapeutics, INC. | $106.98 | 2023-2024 | Auvelity |
| Harmony Biosciences LLC | $96.98 | 2025 | |
| Esperion Therapeutics, INC. | $92.54 | 2021-2024 | Nexletol |
| Lundbeck LLC | $85.57 | 2024 | Rexulti |
| Insmed, INC. | $82.70 | 2020-2025 | Brinsupri, Arikayce |
| Antares Pharma, INC. | $60.03 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Otsuka America Pharmaceutical, INC. | $57.30 | 2022-2023 | Abilify Maintena |
| Allergan, INC. | $55.29 | 2020 | |
| Currax Pharmaceuticals LLC | $46.82 | 2023-2025 | Contrave |
| Astellas Pharma US INC | $42.29 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.81 | 2020-2021 | |
| Exact Sciences Corporation | $37.06 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $35.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.11 | 2019 | |
| Indivior INC. | $25.27 | 2020-2021 | |
| Optos, INC. | $21.42 | 2020 | |
| Optinose US, INC. | $20.16 | 2025 | |
| Alkermes, INC. | $18.57 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $16.36 | 2021 | |
| Baxter Healthcare | $16.29 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $16.27 | 2021 | |
| Ge Healthcare | $15.07 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.61 | 2021 | |
| Abbott Laboratories | $12.86 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narinder Arora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.